ELVN 28.02 Enliven Therapeutics, Inc.
| Range: | 9.8-28.62 | Vol Avg: | 243439 | Last Div: | 0 | Changes: | 0.94 |
| Beta: | 0.93 | Cap: | 1.32B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 12 2020 | Empoloyees: | 52 | ||
| CUSIP: | 29337E102 | CIK: | 0001672619 | ISIN: | US29337E1029 | Country: | US |
| CEO: | Mr. Samuel S. Kintz M.B.A. | Website: | https://www.enliventherapeutics.com | ||||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow